• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

He battled AIDS, COVID-19, and Trump. Now, Anthony Fauci is stepping down
Anthony Fauci, the renowned physician-scientist who has led the $6.3 billion National Institute of Allergy and Infectious Diseases (NIAID) for nearly 4 decades and since early 2020 has been the U.S. government’s voice of scientific reason during the COVID-19 pandemic, will step down from government service in December. Fauci, 81, had said in recent interviews that he planned to retire from the government by the end of President Joe Biden’s administration, but did not give a date until today. He said in a statement that although leading NIAID “has been the honor of a lifetime,” he plans to “pursue...
Source: Science of Aging Knowledge Environment - August 22, 2022 Category: Geriatrics Source Type: research

How Convalescent Plasma Could Help Fight COVID-19
The last time most of us gave any thought to antibodies was probably in high school biology, but we’re getting a crash refresher course thanks to COVID-19. They are, after all, the key to our best defenses against SARS-CoV-2, the virus that’s caused the global pandemic. People who have been infected likely rely on antibodies to recover, and antibodies are what vaccines are designed to produce. Or at least that’s what infectious-disease and public-health experts assume for now. Because SARS-CoV-2 is such a new virus, even the world’s best authorities aren’t yet sure what it will take to build p...
Source: TIME: Health - August 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

"Accelerating Medicines Partnership" and other Collaborations to Speed Discovery of New Therapies
AMP - Accelerating Medicines Partnership In February, we wrote about the National Institutes of Health (NIH) announcement of a partnership with ten drug makers, as well as eight non-profit organizations, to accelerate the discovery of new therapies for Alzheimer's disease, type 2 diabetes, rheumatoid arthritis, and lupus. Under the collaboration, termed the Accelerating Medicines Partnership (AMP), the companies and the NIH have agreed to contribute scientists, along with relevant data and samples from clinical trials, and to share costs. The goal is to transform the current model for developing new...
Source: Policy and Medicine - September 19, 2014 Category: American Health Authors: Thomas Sullivan Source Type: blogs